Mechanisms of enterohepatic fibroblast growth factor 15/19 signaling in health and disease

Cytokine and Growth Factor Reviews

Volumn 26, Issue 6, 2015, Pages 625-635

  Jahn, Daniel ^a   Rau, Monika ^a   Hermanns, Heike M ^a   Geier, Andreas ^a  

^a UNIVERSITY HOSPITAL WÜRZBURG   (Germany)

Author keywords

Bile acid signaling; Energy metabolism; Fibroblast growth factor 15 19; Liver disease; Nuclear receptors; Obesity

Indexed keywords

BILE ACID; CELL NUCLEUS RECEPTOR; FIBROBLAST GROWTH FACTOR; FIBROBLAST GROWTH FACTOR 15; FIBROBLAST GROWTH FACTOR 19; FIBROBLAST GROWTH FACTOR RECEPTOR; KLOTHO PROTEIN; UNCLASSIFIED DRUG; FGF19 PROTEIN, HUMAN; FIBROBLAST GROWTH FACTOR 15, MOUSE;

DISEASE COURSE; ENERGY METABOLISM; ENTEROPATHY; GASTROINTESTINAL DISEASE; GLUCOSE METABOLISM; HOMEOSTASIS; HUMAN; INFLAMMATORY BOWEL DISEASE; IRRITABLE COLON; LIPID METABOLISM; LIVER DISEASE; MALABSORPTION; METABOLIC DISORDER; NONHUMAN; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN SECRETION; PROTEIN SYNTHESIS; PROTEIN TARGETING; REGULATORY MECHANISM; SHORT SURVEY; SIGNAL TRANSDUCTION; ADIPOSE TISSUE; ANIMAL; BIOSYNTHESIS; BRAIN; GENETICS; LIVER; METABOLISM; MOUSE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY;

ADIPOSE TISSUE; ANIMALS; BILE ACIDS AND SALTS; BRAIN; DIABETES MELLITUS, TYPE 2; FIBROBLAST GROWTH FACTORS; HOMEOSTASIS; HUMANS; LIPID METABOLISM; LIVER; MICE; OBESITY; SIGNAL TRANSDUCTION;

EID: 84949105963     PISSN: 13596101     EISSN: 18790305     Source Type: Journal    
DOI: 10.1016/j.cytogfr.2015.07.016     Document Type: Short Survey

References (115)

1. Beenken A., Mohammadi M. The FGF family: biology, pathophysiology and therapy. Nat. Rev. Drug Discov. 2009, 8:235-253.
2. Goetz R., Beenken A., Ibrahimi O.A., Kalinina J., Olsen S.K., Eliseenkova A.V., et al. Molecular insights into the klotho-dependent, endocrine mode of action of fibroblast growth factor 19 subfamily members. Mol. Cell. Biol. 2007, 27:3417-3428.
3. Cicione C., Degirolamo C., Moschetta A. Emerging role of fibroblast growth factors 15/19 and 21 as metabolic integrators in the liver. Hepatology 2012, 56:2404-2411.
4. Potthoff M.J., Kliewer S.A., Mangelsdorf D.J. Endocrine fibroblast growth factors 15/19 and 21: from feast to famine. Gene Dev. 2012, 26:312-324.
5. Angelin B., Larsson T.E., Rudling M. Circulating fibroblast growth factors as metabolic regulators-a critical appraisal. Cell Metab. 2012, 16:693-705.
6. Owen B.M., Mangelsdorf D.J., Kliewer S.A. Tissue-specific actions of the metabolic hormones FGF15/19 and FGF21. Trends Endocrinol. Metab.: TEM 2015, 26:22-29.
7. Kurosu H., Kuro M.O. Endocrine fibroblast growth factors as regulators of metabolic homeostasis. Biofactors 2009, 35:52-60.
8. Fon Tacer K., Bookout A.L., Ding X.S., Kurosu H., John G.B., Wang L., et al. Research resource: comprehensive expression atlas of the fibroblast growth factor system in adult mouse. Mol. Endocrinol. 2010, 24:2050-2064.
9. Lefebvre P., Cariou B., Lien F., Kuipers F., Staels B. Role of bile acids and bile acid receptors in metabolic regulation. Physiol. Rev. 2009, 89:147-191.
10. Parks D.J., Blanchard S.G., Bledsoe R.K., Chandra G., Consler T.G., Kliewer S.A., et al. Bile acids: natural ligands for an orphan nuclear receptor. Science 1999, 284:1365-1368.
11. Makishima M., Okamoto A.Y., Repa J.J., Tu H., Learned R.M., Luk A., et al. Identification of a nuclear receptor for bile acids. Science 1999, 284:1362-1365.
12. Wang H., Chen J., Hollister K., Sowers L.C., Forman B.M. Endogenous bile acids are ligands for the nuclear receptor FXR/BAR. Mol. Cell 1999, 3:543-553.
13. Goodwin B., Jones S.A., Price R.R., Watson M.A., McKee D.D., Moore L.B., et al. A regulatory cascade of the nuclear receptors FXR, SHP-1, and LRH-1 represses bile acid biosynthesis. Mol. Cell 2000, 6:517-526.
14. Lu T.T., Makishima M., Repa J.J., Schoonjans K., Kerr T.A., Auwerx J., et al. Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. Mol. Cell 2000, 6:507-515.
15. Pandak W.M., Li Y.C., Chiang J.Y., Studer E.J., Gurley E.C., Heuman D.M., et al. Regulation of cholesterol 7 alpha-hydroxylase mRNA and transcriptional activity by taurocholate and cholesterol in the chronic biliary diverted rat. J. Biol. Chem. 1991, 266:3416-3421.
16. Nagano M., Kuroki S., Mizuta A., Furukawa M., Noshiro M., Chijiiwa K., et al. Regulation of bile acid synthesis under reconstructed enterohepatic circulation in rats. Steroids 2004, 69:701-709.
17. Holt J.A., Luo G., Billin A.N., Bisi J., McNeill Y.Y., Kozarsky K.F., et al. Definition of a novel growth factor-dependent signal cascade for the suppression of bile acid biosynthesis. Genes Dev. 2003, 17:1581-1591.
18. Inagaki T., Choi M., Moschetta A., Peng L., Cummins C.L., McDonald J.G., et al. Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis. Cell Metab. 2005, 2:217-225.
19. Lundasen T., Galman C., Angelin B., Rudling M. Circulating intestinal fibroblast growth factor 19 has a pronounced diurnal variation and modulates hepatic bile acid synthesis in man. J. Intern. Med. 2006, 260:530-536.
20. Kim I., Ahn S.H., Inagaki T., Choi M., Ito S., Guo G.L., et al. Differential regulation of bile acid homeostasis by the farnesoid X receptor in liver and intestine. J. Lipid Res. 2007, 48:2664-2672.
21. Kurosu H., Choi M., Ogawa Y., Dickson A.S., Goetz R., Eliseenkova A.V., et al. Tissue-specific expression of beta Klotho and fibroblast growth factor (FGF) receptor Isoforms determines metabolic activity of FGF19 and FGF21. J. Biol. Chem. 2007, 282:26687-26695.
22. Lin B.C., Wang M., Blackmore C., Desnoyers L.R. Liver-specific activities of FGF19 require Klotho beta. J. Biol. Chem. 2007, 282:27277-27284.
23. Wu X., Ge H., Gupte J., Weiszmann J., Shimamoto G., Stevens J., et al. Co-receptor requirements for fibroblast growth factor-19 signaling. J. Biol. Chem. 2007, 282:29069-29072.
24. Li S.W., Hsu D.D.F., Li B., Luo X.L., Alderson N., Qiao L.P., et al. Cytoplasmic tyrosine phosphatase Shp2 coordinates hepatic regulation of bile acid and FGF15/19 signaling to repress bile acid synthesis. Cell Metab. 2014, 20:320-332.
25. Yu C., Wang F., Kan M., Jin C., Jones R.B., Weinstein M., et al. Elevated cholesterol metabolism and bile acid synthesis in mice lacking membrane tyrosine kinase receptor FGFR4. J. Biol. Chem. 2000, 275:15482-15489.
26. Ito S., Fujimori T., Furuya A., Satoh J., Nabeshima Y. Impaired negative feedback suppression of bile acid synthesis in mice lacking betaKlotho. J. Clin. Invest. 2005, 115:2202-2208.
27. Tomiyama K., Maeda R., Urakawa I., Yamazaki Y., Tanaka T., Ito S., et al. Relevant use of Klotho in FGF19 subfamily signaling system in vivo. Proc. Natl. Acad. Sci. U. S. A. 2010, 107:1666-1671.
28. Katafuchi T., Esterhazy D., Lemoff A., Ding X., Sondhi V., Kliewer S.A., et al. Detection of FGF15 in plasma by stable isotope standards and capture by anti-peptide antibodies and targeted mass spectrometry. Cell Metab. 2015, 21:898-904.
29. Miao J., Xiao Z., Kanamaluru D., Min G., Yau P.M., Veenstra T.D., et al. Bile acid signaling pathways increase stability of Small Heterodimer Partner (SHP) by inhibiting ubiquitin-proteasomal degradation. Genes Dev. 2009, 23:986-996.
30. Seok S., Kanamaluru D., Xiao Z., Ryerson D., Choi S.E., Suino-Powell K., et al. Bile acid signal-induced phosphorylation of small heterodimer partner by protein kinase Czeta is critical for epigenomic regulation of liver metabolic genes. J. Biol. Chem. 2013, 288:23252-23263.
31. Kir S., Zhang Y., Gerard R.D., Kliewer S.A., Mangelsdorf D.J. Nuclear receptors HNF4 alpha and LRH-1 cooperate in regulating Cyp7a1 in vivo. J. Biol. Chem. 2012, 287:41334-41341.
32. Song K.H., Li T.G., Owsley E., Strom S., Chiang J.Y.L. Bile acids activate fibroblast growth factor 19 signaling in human hepatocytes to inhibit cholesterol 7 alpha-hydroxylase gene expression. Hepatology 2009, 49:297-305.
33. Kong B., Wang L., Chiang J.Y.L., Zhang Y.C., Klaassen C.D., Guo G.L. Mechanism of tissue-specific farnesoid X receptor in suppressing the expression of genes in bile-acid synthesis in mice. Hepatology 2012, 56:1034-1043.
34. Shin D.J., Osborne T.F. FGF15/FGFR4 integrates growth factor signaling with hepatic bile acid metabolism and insulin action. J. Biol. Chem. 2009, 284:11110-11120.
35. Tomlinson E., Fu L., John L., Hultgren B., Huang X.J., Renz M., et al. Transgenic mice expressing human fibroblast growth factor-19 display increased metabolic rate and decreased adiposity. Endocrinology 2002, 143:1741-1747.
36. Fu L., John L.M., Adams S.H., Yu X.X., Tomlinson E., Renz M., et al. Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes. Endocrinology 2004, 145:2594-2603.
37. Schmitt J., Kong B., Stieger B., Tschopp O., Schultze S.M., Rau M., et al. Protective effects of farnesoid X receptor (FXR) on hepatic lipid accumulation are mediated by hepatic FXR and independent of intestinal FGF 15 signal. Liver Int. 2015, 35:1133-1144.
38. Bhatnagar S., Damron H.A., Hillgartner F.B. Fibroblast growth factor-19, a novel factor that inhibits hepatic fatty acid synthesis. J. Biol. Chem. 2009, 284:10023-10033.
39. Kir S., Beddow S.A., Samuel V.T., Miller P., Previs S.F., Suino-Powell K., et al. FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis. Science 2011, 331:1621-1624.
40. Potthoff M.J., Boney-Montoya J., Choi M., He T., Sunny N.E., Satapati S., et al. FGF15/19 regulates hepatic glucose metabolism by inhibiting the CREB-PGC-1alpha pathway. Cell Metab. 2011, 13:729-738.
41. Morton G.J., Matsen M.E., Bracy D.P., Meek T.H., Nguyen H.T., Stefanovski D., et al. FGF19 action in the brain induces insulin-independent glucose lowering. J. Clin. Invest. 2013, 123:4799-4808.
42. Ryan K.K., Kohli R., Gutierrez-Aguilar R., Gaitonde S.G., Woods S.C., Seeley R.J. Fibroblast growth factor-19 action in the brain reduces food intake and body weight and improves glucose tolerance in male rats. Endocrinology 2013, 154:9-15.
43. Marcelin G., Jo Y.H., Li X., Schwartz G.J., Zhang Y., Dun N.J., et al. Central action of FGF19 reduces hypothalamic AGRP/NPY neuron activity and improves glucose metabolism. Mol. Metab. 2014, 3:19-28.
44. Perry R.J., Lee S., Ma L., Zhang D., Schlessinger J., Shulman G.I. FGF1 and FGF19 reverse diabetes by suppression of the hypothalamic-pituitary-adrenal axis. Nat. Commun. 2015, 6:6980.
45. Wu X.L., Ge H.F., Baribault H., Gupte J., Weiszmann J., Lemon B., et al. Dual actions of fibroblast growth factor 19 on lipid metabolism. J. Lipid Res. 2013, 54:325-332.
46. Huang X.Q., Yang C.F., Luo Y.D., Jin C.L., Wang F., McKeehan W.L. FGFR4 prevents hyperlipidemia and insulin resistance but underlies high-fat diet-induced fatty liver. Diabetes 2007, 56:2501-2510.
47. Wu A.L., Coulter S., Liddle C., Wong A.N., Eastham-Anderson J., French D.M., et al. FGF19 regulates cell proliferation, glucose and bile acid metabolism via FGFR4-dependent and independent pathways. Plos One 2011, 6.
48. Wu X.L., Ge H.F., Lemon B., Weiszmann J., Gupte J., Hawkins N., et al. Selective activation of FGFR4 by an FGF19 variant does not improve glucose metabolism in ob/ob mice. Proc. Natl. Acad. Sci. U. S. A. 2009, 106:14379-14384.
49. Ge H.F., Baribault H., Vonderfecht S., Lemon B., Weiszmann J., Gardner J., et al. Characterization of a FGF19 variant with altered receptor specificity revealed a central role for FGFR1c in the regulation of glucose metabolism. Plos One 2012, 7.
50. Li J.L., Pircher P.C., Schulman I.G., Westin S.K. Regulation of complement C3 expression by the bile acid receptor FXR. J. Biol. Chem. 2005, 280:7427-7434.
51. Miyata M., Hata T., Yamakawa H., Kagawa T., Yoshinari K., Yamazoe Y. Involvement of multiple elements in FXR-mediated transcriptional activation of FGF19. J. Steroid Biochem. Mol. Biol. 2012, 132:41-47.
52. Zhang J.H., Nolan J.D., Kennie S.L., Johnston I.M., Dew T., Dixon P.H., et al. Potent stimulation of fibroblast growth factor 19 expression in the human ileum by bile acids. Am. J. Physiol. Gastrointest. Liver Physiol. 2013, 304:G940-G948.
53. Wistuba W., Gnewuch C., Liebisch G., Schmitz G., Langmann T. Lithocholic acid induction of the FGF19 promoter in intestinal cells is mediated by PXR. World J. Gastroenterol.: WJG 2007, 13:4230-4235.
54. Wang H.W., Venkatesh M., Li H., Goetz R., Mukherjee S., Biswas A., et al. Pregnane X receptor activation induces FGF19-dependent tumor aggressiveness in humans and mice. J. Clin. Invest. 2011, 121:3220-3232.
55. Schmidt D.R., Holmstrom S.R., Fon Tacer K., Bookout A.L., Kliewer S.A., Mangelsdorf D.J. Regulation of bile acid synthesis by fat-soluble vitamins A and D. J. Biol. Chem. 2010, 285:14486-14494.
56. Vergnes L., Lee J.M., Chin R.G., Auwerx J., Reue K. Diet1 functions in the FGF15/19 enterohepatic signaling axis to modulate bile acid and lipid levels. Cell Metab. 2013, 17:916-928.
57. Reue K., Lee J.M., Vergnes L. Regulation of bile acid homeostasis by the intestinal Diet1-FGF15/19 axis. Curr. Opin. Lipidol. 2014, 25:140-147.
58. Sayin S.I., Wahlstrom A., Felin J., Jantti S., Marschall H.U., Bamberg K., et al. Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. Cell Metab. 2013, 17:225-235.
59. Hu X., Bonde Y., Eggertsen G., Rudling M. Muricholic bile acids are potent regulators of bile acid synthesis via a positive feedback mechanism. J. Intern. Med. 2014, 275:27-38.
60. Degirolamo C., Rainaldi S., Bovenga F., Murzilli S., Moschetta A. Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. Cell Rep. 2014, 7:12-18.
61. Out C., Patankar J.V., Doktorova M., Boesjes M., Bos T., de Boer S., et al. Gut microbiota inhibit Asbt-dependent intestinal bile acid reabsorption via Gata 4. J. Hepatol. 2015.
62. Miyata M., Takamatsu Y., Kuribayashi H., Yamazoe Y. Administration of ampicillin elevates hepatic primary bile acid synthesis through suppression of ileal fibroblast growth factor 15 expression. J. Pharmacol. Exp. Ther. 2009, 331:1079-1085.
63. Schreuder T.C.M.A., Marsman H.A., Lenicek M., van Werven J.R., Nederveen A.J., Jansen P.L.M., et al. The hepatic response to FGF19 is impaired in patients with nonalcoholic fatty liver disease and insulin resistance. Am. J. Physiol-Gastrointest. Liver 2010, 298:G440-G445.
64. Morton G.J., Kaiyala K.J., Foster-Schubert K.E., Cummings D.E., Schwartz M.W. Carbohydrate feeding dissociates the postprandial FGF19 response from circulating bile acid levels in humans. J Clin. Endocr. Metab. 2014, 99:E241-E245.
65. Schmid A., Leszczak S., Ober I., Karrasch T., Schaffler A. Short-term and divergent regulation of FGF-19 and FGF-21 during Oral Lipid Tolerance Test but not Oral Glucose Tolerance Test. Exp. Clin. Endocrinol. Diab.: Off. J., German Soc. Endocrinol. German Diab. Assoc. 2015, 123:88-94.
66. Schaap F.G., van der Gaag N.A., Gouma D.J., Jansen P.L.M. High expression of the bile salt-homeostatic hormone fibroblast growth factor 19 in the liver of patients with extrahepatic cholestasis. Hepatology 2009, 49:1228-1235.
67. Zweers S.J., Booij K.A., Komuta M., Roskams T., Gouma D.J., Jansen P.L., et al. The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract. Hepatology 2012, 55:575-583.
68. Choi M., Moschetta A., Bookout A.L., Peng L., Umetani M., Holmstrom S.R., et al. Identification of a hormonal basis for gallbladder filling. Nat. Med. 2006, 12:1253-1255.
69. Krawczyk M., Acalovschi M., Lammert F. Genetic study of FGF19 receptor variants in gallstone disease. Hepatology 2012, 56:2424.
70. Renner O., Harsch S., Matysik S., Lutjohann D., Schmitz G., Stange E.F. Upregulation of hepatic bile acid synthesis via fibroblast growth factor 19 is defective in gallstone disease but functional in overweight individuals. United Eur. Gastroenterol. J. 2014, 2:216-225.
71. Stejskal D., Karpisek M., Hanulova Z., Stejskal P. Fibroblast growth factor-19: development, analytical characterization and clinical evaluation of a new ELISA test. Scand. J. Clin. Lab. Invest. 2008, 68:501-507.
72. Barutcuoglu B., Basol G., Cakir Y., Cetinkalp S., Parildar Z., Kabaroglu C., et al. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome. Ann. Clin. Lab. Sci. 2011, 41:390-396.
73. Wojcik M., Janus D., Dolezal-Oltarzewska K., Kalicka-Kasperczyk A., Poplawska K., Drozdz D., et al. A decrease in fasting FGF19 levels is associated with the development of non-alcoholic fatty liver disease in obese adolescents. J. Pediatr. Endocr. Met. 2012, 25:1089-1093.
74. Gallego-Escuredo J.M., Gomez-Ambrosi J., Catalan V., Domingo P., Giralt M., Fruhbeck G., et al. Opposite alterations in FGF21 and FGF 19 levels and disturbed expression of the receptor machinery for endocrine FGFs in obese patients. Int. J. Obes. 2015, 39:121-129.
75. Eren F., Kurt R., Ermis F., Atug O., Imeryuz N., Yilmaz Y. Preliminary evidence of a reduced serum level of fibroblast growth factor 19 in patients with biopsy-proven nonalcoholic fatty liver disease. Clin. Biochem. 2012, 45:655-658.
76. Mraz M., Lacinova Z., Kavalkova P., Haluzikova D., Trachta P., Drapalova J., et al. Serum concentrations of fibroblast growth factor 19 in patients with obesity and type 2 diabetes mellitus: the influence of acute hyperinsulinemia, very-low calorie diet and PPAR-alpha agonist treatment. Physiol. Res. 2011, 60:627-636.
77. Alisi A., Ceccarelli S., Panera N., Prono F., Petrini S., De Stefanis C., et al. Association between serum atypical fibroblast growth factors 21 and 19 and pediatric nonalcoholic fatty liver disease. Plos One 2013, 8.
78. Fu T., Choi S.E., Kim D.H., Seok S., Suino-Powell K.M., Xu H.E., et al. Aberrantly elevated microRNA-34a in obesity attenuates hepatic responses to FGF19 by targeting a membrane coreceptor beta-Klotho. Proc. Natl. Acad. Sci. U. S. A. 2012, 109:16137-16142.
79. Jansen P.L., van Werven J., Aarts E., Berends F., Janssen I., Stoker J., et al. Alterations of hormonally active fibroblast growth factors after Roux-en-Y gastric bypass surgery. Dig. Dis. 2011, 29:48-51.
80. Pournaras D.J., Glicksman C., Vincent R.P., Kuganolipava S., Alaghband-Zadeh J., Mahon D., et al. The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control. Endocrinology 2012, 153:3613-3619.
81. Gerhard G.S., Styer A.M., Wood G.C., Roesch S.L., Petrick A.T., Gabrielsen J., et al. A role for fibroblast growth factor 19 and bile acids in diabetes remission after Roux-en-Y gastric bypass. Diab. Care 2013, 36:1859-1864.
82. Haluzikova D., Lacinova Z., Kavalkova P., Drapalova J., Krizova J., Bartlova M., et al. Laparoscopic sleeve gastrectomy differentially affects serum concentrations of FGF-19 and FGF- in morbidly obese subjects. Obesity 2013, 21:1335-1342.
83. Ryan K.K., Tremaroli V., Clemmensen C., Kovatcheva-Datchary P., Myronovych A., Karns R., et al. FXR is a molecular target for the effects of vertical sleeve gastrectomy. Nature 2014, 509:183-188.
84. Jorgensen N.B., Dirksen C., Bojsen-Moller K.N., Kristiansen V.B., Wulff B.S., Rainteau D., et al. Improvements in glucose metabolism early after gastric bypass surgery are not explained by increases in total bile acids and fibroblast growth factor 19 concentrations. J. Clin. Endocrinol. Metab. 2015, 100:E396-E406.
85. Lips M.A., de Groot G.H., Berends F.J., Wiezer R., van Wagensveld B.A., Swank D.J., et al. Calorie restriction and Roux-en-Y gastric bypass have opposing effects on circulating FGF21 in morbidly obese subjects. Clin. Endocrinol. 2014, 81:862-870.
86. Neuschwander-Tetri B.A., Loomba R., Sanyal A.J., Lavine J.E., Van Natta M.L., Abdelmalek M.F., Farnesoid X., et al. Nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial. Lancet 2015, 385:956-965.
87. Mudaliar S., Henry R.R., Sanyal A.J., Morrow L., Marschall H.U., Kipnes M., et al. Efficacy and safety of the farnesoid X receptor agonist obeticholic acid in patients with type 2 diabetes and nonalcoholic fatty liver disease. Gastroenterology 2013, 145:574-582 e1.
88. Lenicek M., Duricova D., Komarek V., Gabrysova B., Lukas M., Smerhovsky Z., et al. Bile acid malabsorption in inflammatory bowel disease: assessment by serum markers. Inflamm. Bowel Dis. 2011, 17:1322-1327.
89. Iwamoto J., Saito Y., Honda A., Miyazaki T., Ikegami T., Matsuzaki Y., Bile X. Acid malabsorption deactivates pregnane receptor in patients with Crohn's disease. Inflamm. Bowel Dis. 2013, 19:1278-1284.
90. Uko V., Thangada S., Radhakrishnan K. Liver disorders in inflammatory bowel disease. Gastroenterol. Res. Pract. 2012, 1.
91. Gizard E., Ford A.C., Bronowicki J.P., Peyrin-Biroulet L. Systematic review: the epidemiology of the hepatobiliary manifestations in patients with inflammatory bowel disease. Aliment Pharm. Ther. 2014, 40:3-15.
92. Wieser V., Gerner R., Moschen A.R., Tilg H. Liver complications in inflammatory bowel diseases. Digest Dis. 2013, 31:233-238.
93. Mutanen A., Lohi J., Heikkila P., Jalanko H., Pakarinen M.P. Loss of ileum decreases serum fibroblast growth factor 19 in relation to liver inflammation and fibrosis in pediatric onset intestinal failure. J. Hepatol. 2015, 62:1391-1397.
94. Pereira-Fantini P.M., Lapthorne S., Joyce S.A., Dellios N.L., Wilson G., Fouhy F., et al. Altered FXR signalling is associated with bile acid dysmetabolism in short bowel syndrome-associated liver disease. J. Hepatol. 2014, 61:1115-1125.
95. Gadaleta R.M., Oldenburg B., Willemsen E.C.L., Spit M., Murzilli S., Salvatore L., et al. Activation of bile salt nuclear receptor FXR is repressed by pro-inflammatory cytokines activating NF-kappa B signaling in the intestine. BBA-Mol. Basis Dis. 2011, 1812:851-858.
96. Jahnel J., Fickert P., Hauer A.C., Hogenauer C., Avian A., Trauner M. Inflammatory bowel disease alters intestinal bile acid transporter expression. Drug Metab. Dispos. 2014, 42:1423-1431.
97. Wojtal K.A., Eloranta J.J., Hruz P., Gutmann H., Drewe J., Staumann A., et al. Changes in mRNA expression levels of solute carrier transporters in inflammatory bowel disease patients. Drug Metab. Dispos. 2009, 37:1871-1877.
98. Jung D., Fantin A.C., Scheurer U., Fried M., Kullak-Ublick G.A. Human ileal bile acid transporter gene ASBT (SLC10A2) is transactivated by the glucocorticoid receptor. Gut 2004, 53:78-84.
99. Zhou X., Cao L., Jiang C., Xie Y., Cheng X., Krausz K.W., et al. PPARalpha-UGT axis activation represses intestinal FXR-FGF15 feedback signalling and exacerbates experimental colitis. Nat. Commun. 2014, 5:4573.
100. Walters J.R.F., Tasleem A.M., Omer O.S., Brydon W.G., Dew T., Le Roux C.W. A new mechanism for bile acid diarrhea: defective feedback inhibition of bile acid biosynthesis. Clin. Gastroenterol. Hepatol. 2009, 7:1189-1194.
101. Pattni S.S., Brydon W.G., Dew T., Johnston I.M., Nolan J.D., Srinivas M., et al. Fibroblast growth factor 19 in patients with bile acid diarrhoea: a prospective comparison of FGF19 serum assay and SeHCAT retention. Aliment Pharm. Ther. 2013, 38:967-976.
102. Pattni S.S., Brydon W.G., Dew T., Walters J.R. Fibroblast growth factor 19 and 7 alpha-hydroxy-4-cholesten-3-one in the diagnosis of patients with possible bile acid diarrhea. Clin. Transl. Gastroenterol. 2012, 3:e18.
103. Walters J.R., Johnston I.M., Nolan J.D., Vassie C., Pruzanski M.E., Shapiro D.A. The response of patients with bile acid diarrhoea to the farnesoid X receptor agonist obeticholic acid. Aliment Pharmacol. Ther. 2014.
104. Bajor A., Tornblom H., Rudling M., Ung K.A., Simren M. Increased colonic bile acid exposure: a relevant factor for symptoms and treatment in IBS. Gut 2015, 64:84-92.
105. Wong B.S., Camilleri M., Carlson P.J., Guicciardi M.E., Burton D., McKinzie S., et al. A Klotho beta variant mediates protein stability and associates with colon transit in irritable bowel syndrome with diarrhea. Gastroenterology 2011, 140:1934-1942.
106. Uriarte I., Fernandez-Barrena M.G., Monte M.J., Latasa M.U., Chang H.C.Y., Carotti S., et al. Identification of fibroblast growth factor 15 as a novel mediator of liver regeneration and its application in the prevention of post-resection liver failure in mice. Gut 2013, 62:899-910.
107. Nicholes K., Guillet S., Tomlinson E., Hillan K., Wright B., Frantz G.D., et al. A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice. Am. J. Pathol. 2002, 160:2295-2307.
108. Desnoyers L.R., Pai R., Ferrando R.E., Hotzel K., Le T., Ross J., et al. Targeting FGF19 inhibits tumor growth in colon cancer xenograft and FGF19 transgenic hepatocellular carcinoma models. Oncogene 2008, 27:85-97.
109. French D.M., Lin B.C., Wang M., Adams C., Shek T., Hotzel K., et al. Targeting FGFR4 inhibits hepatocellular carcinoma in preclinical mouse models. Plos One 2012, 7:e36713.
110. Sawey E.T., Chanrion M., Cai C., Wu G., Zhang J., Zender L., et al. Identification of a therapeutic strategy targeting amplified FGF in liver cancer by Oncogenomic screening. Cancer Cell 2011, 19:347-358.
111. Hagel M., Miduturu C., Sheets M., Rubin N., Weng W., Stransky N., et al. First selective small molecule inhibitor of FGFR4 for the treatment of hepatocellular carcinomas with an activated fgfr4 signaling pathway. Cancer Discov. 2015, 5:424-437.
112. Uriarte I., Latasa M.U., Carotti S., Fernandez-Barrena M.G., Garcia-Irigoyen O., Elizalde M., et al. Ileal FGF15 contributes to fibrosis-associated hepatocellular carcinoma development. Int. J. Cancer 2015, 136:2469-2475.
113. Wu X., Ge H., Lemon B., Vonderfecht S., Baribault H., Weiszmann J., et al. Separating mitogenic and metabolic activities of fibroblast growth factor 19 (FGF19). Proc. Natl. Acad. Sci. U. S. A. 2010, 107:14158-14163.
114. Zhou M., Wang X., Phung V., Lindhout D.A., Mondal K., Hsu J.Y., et al. Separating tumorigenicity from bile acid regulatory activity for endocrine hormone FGF19. Cancer Res. 2014, 74:3306-3316.
115. Luo J., Ko B., Elliott M., Zhou M., Lindhout D.A., Phung V., et al. A nontumorigenic variant of FGF19 treats cholestatic liver diseases. Sci. Transl. Med. 2014, 6.